Process for the preparation of a galacto-oligosaccharide preparation, which process comprises the step of contacting a lactulose-containing feed with a beta-galactosidase derived from Papiliotrema terrestris. The resulting galacto-oligosaccharide is acceptable to subjects suffering from GOS-related allergy and subjects having lactose intolerance.

A purpose of the present invention is to provide a method for producing a glycoside compound having a high purity. The present invention provides a method for producing a glycoside compound represented by formula (3) (wherein B.sup.a, i-Pr and n are the same as those defined below), which comprises reacting a glycoside compound of formula (1) (wherein B.sup.a represents an adenine group which may be optionally substituted with an acyl group, and i-Pr represents an isopropyl group) with an ether compound of formula (2) (wherein R.sup.1 represents a C1-C6 alkyl group or a phenyl group, and n is 0 or 1) in one or more solvents selected from tetrahydropyran and 4-methyltetrahydropyran in the presence of one or more halogenated agents selected from halogen, N-halogenated succinimide, and N-halogenated hydantoin.

##STR00001##

A purpose of the present invention is to provide a method for producing a glycoside compound having a high purity. The present invention provides a method for producing a glycoside compound represented by formula (3) (wherein B.sup.a, i-Pr and n are the same as those defined below), which comprises reacting a glycoside compound of formula (1) (wherein B.sup.a represents an adenine group which may be optionally substituted with an acyl group, and i-Pr represents an isopropyl group) with an ether compound of formula (2) (wherein R.sup.1 represents a C1-C6 alkyl group or a phenyl group, and n is 0 or 1) in one or more solvents selected from tetrahydropyran and 4-methyltetrahydropyran in the presence of one or more halogenated agents selected from halogen, N-halogenated succinimide, and N-halogenated hydantoin.

##STR00001##

The present invention provides an amidite compound capable of improving a yield and a purity of a polyoligonucleotide, a glycoside compound as an intermediate thereof, and a production method for a polynucleotide using the amidite compound. The present invention also provides an amidite compound of formula (1) capable of improving a yield and a purity of a polyoligonucleotide, a glycoside compound of formula (10) (in formulae (10) and (1), B.sup.a, R.sup.a, R.sup.b, R.sup.c, G.sup.1, G.sup.2, and G.sup.3 are as defined in the description, and R is represented by the following formulae), and a production method for a polynucleotide using the amidite compound.

The present invention provides an amidite compound capable of improving a yield and a purity of a polyoligonucleotide, a glycoside compound as an intermediate thereof, and a production method for a polynucleotide using the amidite compound. The present invention also provides an amidite compound of formula (1) capable of improving a yield and a purity of a polyoligonucleotide, a glycoside compound of formula (10) (in formulae (10) and (1), B.sup.a, R.sup.a, R.sup.b, R.sup.c, G.sup.1, G.sup.2, and G.sup.3 are as defined in the description, and R is represented by the following formulae), and a production method for a polynucleotide using the amidite compound.

Provided is a method of treating cancer cells localized in the lung by administering to such patients a therapeutically effective amount of a liposomal annamycin formulation (L-Ann).

Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 infection.

A microfluidic valve includes a carrier layer and a flexible membrane layer arranged on a surface of the carrier layer. The surface of the carrier layer has a valve chamber in the form of a spherical cap and a membrane formed by the flexible membrane layer covers at least the valve chamber. A plurality of microfluidic channels opening into the valve chamber are formed in the surface of the carrier layer. Moreover, an inflow channel and an outflow channel are connected to one another by a microfluidic connection channel. The connection channel and the valve chamber are positioned relative to each other in such a way that in the closed state of the membrane, a fluid can flow from the inflow channel via the connection channel into the outflow channel to bridge the valve chamber, while the at least one supply channel is closed by the membrane.

A microfluidic valve includes a carrier layer and a flexible membrane layer arranged on a surface of the carrier layer. The surface of the carrier layer has a valve chamber in the form of a spherical cap and a membrane formed by the flexible membrane layer covers at least the valve chamber. A plurality of microfluidic channels opening into the valve chamber are formed in the surface of the carrier layer. Moreover, an inflow channel and an outflow channel are connected to one another by a microfluidic connection channel. The connection channel and the valve chamber are positioned relative to each other in such a way that in the closed state of the membrane, a fluid can flow from the inflow channel via the connection channel into the outflow channel to bridge the valve chamber, while the at least one supply channel is closed by the membrane.

A method for subjecting a compound [A] having a hydroxyl group or a primary or secondary amino group and a compound [B] having a substituent containing a phosphorus atom to a condensation reaction to prepare a compound [C] represented by the following general formula [C]: ##STR00001##
wherein the condensation reaction is carried out in a mixed solvent containing a polar solvent and a halogen solvent as a reaction solvent.